126 related articles for article (PubMed ID: 9149899)
1. Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome.
Eng C; Schneider K; Fraumeni JF; Li FP
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):379-83. PubMed ID: 9149899
[No Abstract] [Full Text] [Related]
2. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
Nemunaitis JM; Nemunaitis J
Future Oncol; 2008 Dec; 4(6):759-68. PubMed ID: 19086841
[TBL] [Abstract][Full Text] [Related]
3. Collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome.
Li FP; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1994 Dec; 3(8):715-7. PubMed ID: 7881346
[No Abstract] [Full Text] [Related]
4. [New knowledge of Li-Fraumeni syndrome].
Funato M; Kondo N
Gan To Kagaku Ryoho; 2013 Feb; 40(2):148-53. PubMed ID: 23411951
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and imaging surveillance in Li-Fraumeni syndrome.
Raskind WH; Hisama FM; Bennett RL
Lancet Oncol; 2016 Nov; 17(11):e472. PubMed ID: 27819239
[No Abstract] [Full Text] [Related]
6. 2009 version of the Chompret criteria for Li Fraumeni syndrome.
Tinat J; Bougeard G; Baert-Desurmont S; Vasseur S; Martin C; Bouvignies E; Caron O; Bressac-de Paillerets B; Berthet P; Dugast C; Bonaïti-Pellié C; Stoppa-Lyonnet D; Frébourg T
J Clin Oncol; 2009 Sep; 27(26):e108-9; author reply e110. PubMed ID: 19652052
[No Abstract] [Full Text] [Related]
7. Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply.
Villani A; Malkin D
Lancet Oncol; 2016 Nov; 17(11):e473. PubMed ID: 27819240
[No Abstract] [Full Text] [Related]
8. Two Clinical Cases of Li-Fraumeni Syndrome and Prostate Cancer: Genetic Counseling and Clinical-Surgical Management.
Abad-Carratalà G; Blanco-Silvestre M; Sánchez-Llopis A; Monsonís-Usó R; Martínez-Cadenas C; Martínez-Meneu P; Amaya-Barroso B; Muñoz-Vicente E; Garau-Perelló C; Ponce-Blasco P; Barrios-Arnau L; Bosquet-Sanz M; Rodrigo-Aliaga M
Clin Genitourin Cancer; 2022 Dec; 20(6):581-585. PubMed ID: 35831225
[No Abstract] [Full Text] [Related]
9. Genotype Versus Phenotype: The Yin and Yang of Germline TP53 Mutations in Li-Fraumeni Syndrome.
Nichols KE; Malkin D
J Clin Oncol; 2015 Jul; 33(21):2331-3. PubMed ID: 26101242
[No Abstract] [Full Text] [Related]
10. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel TP53 germline mutation in a large Italian Li-Fraumeni syndrome Family.
Capra V; Consales A; Nozza P; Monti P; Inga A; Fronza G
Pediatr Blood Cancer; 2009 Feb; 52(2):303-4. PubMed ID: 18937320
[No Abstract] [Full Text] [Related]
12. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
[TBL] [Abstract][Full Text] [Related]
13. Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome.
Lin MT; Shieh JJ; Chang JH; Chang SW; Chen TC; Hsu WH
Pediatr Blood Cancer; 2009 Apr; 52(4):541-4. PubMed ID: 19101993
[TBL] [Abstract][Full Text] [Related]
14. Is Li-Fraumeni syndrome really much more common?
Thomas DM
Hum Mutat; 2017 Dec; 38(12):1619. PubMed ID: 29091331
[No Abstract] [Full Text] [Related]
15. Li-Fraumeni versus Pseudo-Li-Fraumeni Syndrome: Key Insights for Interpreting Next-Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes.
Sorscher S; Desnoyers R; Ouyang K; Ramkissoon S
Oncologist; 2017 Sep; 22(9):1084-1085. PubMed ID: 28592622
[TBL] [Abstract][Full Text] [Related]
16. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
Kouidou S; Malousi A; Maglaveras N
Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
[TBL] [Abstract][Full Text] [Related]
17. Li-Fraumeni syndrome--a molecular and clinical review.
Varley JM; Evans DG; Birch JM
Br J Cancer; 1997; 76(1):1-14. PubMed ID: 9218725
[No Abstract] [Full Text] [Related]
18. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
19. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
20. [Li-Fraumeni syndrome: clinico-molecular diagnostics and medico-genetic counseling].
Liubchenko LN
Vestn Ross Akad Med Nauk; 2011; (12):47-52. PubMed ID: 22379889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
